Author:
Wang Haiyang,Mustafa Abdulkadir,Liu Shixi,Liu Jun,Lv Dan,Yang Hui,Zou Jian
Subject
Pharmacology (medical),Pharmacology
Reference40 articles.
1. Immunotherapy for recurrent/metastatic head and neck cancer;Alfieri;Curr. Opin. Otolaryngol. Head Neck Surg.,2018
2. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome;Alsaab;Front. Pharmacol.,2017
3. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK Cells;Andre;Cell,2018
4. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II Study;Bauml;J. Clin. Oncol.,2017
5. FT500, an off-the-shelf NK cell cancer immunotherapy derived from a master pluripotent cell line, enhances T-cell activation and recruitment to overcome checkpoint blockade resistance;Bjordahl;Cancer Res.,2018
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献